Tyloxapol: Difference between revisions
KolbertBot (talk | contribs) m Bot: HTTP→HTTPS (v481) |
|||
Line 73: | Line 73: | ||
| year = 1992 |
| year = 1992 |
||
| pmid = 1555424 |
| pmid = 1555424 |
||
}}</ref> administered by inhalation through a [[nebulizer]]<ref>Drugs.com: [ |
}}</ref> administered by inhalation through a [[nebulizer]]<ref>Drugs.com: [https://www.drugs.com/dict/tyloxapol.html Tyloxapol definition]</ref> or with a stream of oxygen. |
||
With [[intraperitoneal injection]], tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of [[triglyceride]]-rich [[lipoprotein]]s. This mechanism is used to induce experimental [[hyperlipidemia]] in animals.<ref>{{Cite journal |
With [[intraperitoneal injection]], tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of [[triglyceride]]-rich [[lipoprotein]]s. This mechanism is used to induce experimental [[hyperlipidemia]] in animals.<ref>{{Cite journal |
Revision as of 21:53, 23 January 2018
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.209.660 |
Chemical and physical data | |
Formula | (C15H21O(C2H4O)m)n |
Molar mass | variable |
(what is this?) (verify) |
Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.
With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]
Tyloxapol is the main active ingredient of the medical device Tacholiquin®. Tacholiquin® is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are Exosurf and Alevaire.
References
- ^ Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653. PMID 8151722.
- ^ Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.
- ^ Drugs.com: Tyloxapol definition
- ^ Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and Molecular Pathology. 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.